Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes

✍ Scribed by Jan Vaage; Dorothy Donovan; Eirin Wipff; Robert Abra; Gail Colbern; Paul Uster; Peter Working

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: French
• Weight: 62 KB
• Volume: 80
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(19990105)80:1<134::aid-ijc24>3.0.co;2-q

✦ Synopsis

We compared the therapeutic effects of low doses of cisplatin and doxorubicin hydrochloride encapsulated in longcirculating liposomes composed of cholesterol/hydrogenated soy phosphatidylcholine-polyethylene glycol-distearoyl-phosphatidyl-ethanolamine. The encapsulation of cisplatin and doxorubicin in these liposomes made ineffectively low doses of the free drugs able to inhibit the growth of and affect cures of a human colonic carcinoma growing in nude mice. Liposome-encapsulated cisplatin had minor systemic toxic side effects indicated by an average 9% weight loss which was recovered 3-4 weeks after the last treatment. Toxicity was not observed in mice treated with liposome-encapsulated doxorubicin.